#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Aplastic anaemia Acute respiratory distress syndrome Thrombocytosis Facioscapulohumeral muscular dystrophy Leukoencephalopathy Langerhans cell sarcoma Glomerulonephritis membranoproliferative Immune-mediated myositis Palmar-plantar erythrodysaesthesia syndrome Juvenile psoriatic arthritis Frostbite Obliterative bronchiolitis Arrhythmogenic right ventricular dysplasia Adrenogenital syndrome Retinal dystrophy More trials…

    Learn about Rare Diseases

    Adrenocortical carcinoma – Life with Disease Synovial sarcoma – Trials in Disease Advanced systemic mastocytosis – Life with Disease Marginal zone lymphoma refractory – Trials in Disease Idiopathic pulmonary fibrosis – Life with Disease Hepatoblastoma Haemophagocytic lymphohistiocytosis – Diagnostics Burkitt’s lymphoma – Diagnostics Mucopolysaccharidosis – Basic Information Idiopathic inflammatory myopathy More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VGA039 Alitretinoin Epacadostat Heterodimeric Interleukin-15 Terbinafine Latozinemab Mbf-118 Vindesine Sulfate Imiglucerase Diphenhydramine Hydrochloride Milademetan Ergocalciferol Pembrolizumab Alanine R2R01 Ly3473329 Inebilizumab Decitabine KETOROLAC TROMETAMOL Zidesamtinib More therapies…

    Learn about Your Condition

    Muscle strain Burning mouth syndrome Epidermolysis bullosa Cardiac failure chronic Renal cancer recurrent Poor quality sleep Corneal dystrophy Mucopolysaccharidosis II Apheresis Obstructive pancreatitis Osteogenesis imperfecta Intestinal infarction Synovial sarcoma recurrent Acute promyelocytic leukaemia Developmental hip dysplasia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Lupus nephritis

  • A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome

    Recruiting

    4 1 1
    Investigated Drugs:
    • Kyv-101
    Germany

  • Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Entecavir
    • Ianalumab
    • Tenofovir Disoproxil
    Czechia France Hungary Lithuania Romania Spain

  • Safety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Lupus nephritis
    Investigated Drugs:
    • Transpocart19
    Spain

  • A Study of Obecabtagene Autoleucel for Patients with Severe Lupus and Active Kidney Inflammation Not Responding to Standard Treatment

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Lupus nephritis
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22
    • Fludarabine Phosphate
    • Cyclophosphamide
    Greece

  • Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Lupus nephritis
    • Systemic lupus erythematosus
    Investigated Drugs:
    • CC-97540
    • Fludarabine
    • Fludarabine Phosphate
    Austria Belgium Denmark France Germany Italy +3

  • Study on the Effects of Ianalumab with Standard Therapy for Patients with Active Lupus Nephritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lupus nephritis
    Investigated Drugs:
    • Entecavir
    • Ianalumab
    • Tenofovir Disoproxil
    Czechia Estonia France Germany Hungary Italy +3
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!